CAR T cells plus glofitamab for high-risk large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests combining two therapies—a CAR T-cell treatment and an antibody drug called glofitamab—for people with large B-cell lymphoma that has come back or not responded to initial treatment and has certain high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of large B-cell lymphoma that has returned or not responded to at least one prior treatment.
- Your lymphoma cells must have two specific proteins (CD19 and CD20) on their surface.
- You have at least one high-risk feature, such as lymphoma outside the lymph nodes, a tumor larger than 4 cm, or a TP53 gene change.
- You are well enough to have a daily activity level of 0, 1, or 2 on the ECOG scale (able to do most things on your own).
- You have not had a stem cell transplant from a donor, or previous treatment with a CAR T-cell therapy that targets CD19.
- You do not have active hepatitis B or C, HIV, or other uncontrolled infections or medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for patients with large B-cell lymphoma who did not respond well to CAR-T cell therapy (a type of immunotherapy). The study uses tumor testing to guide which drugs to use, aiming to help patients whose cancer has stopped responding or is growing again.
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This study tests a combination of three treatments—rimegepant, glofitamab, and CAR-T cell therapy—for patients with large B-cell lymphoma that has stopped responding to previous treatments. The goal is to see if this combination can help control the cancer and improve survival.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.